Immune Provides Corporate Update Regarding NASDAQ US Listing Status
Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP; the "Company") announced today that on December 1, 2017, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("NASDAQ") in the United States notifying the Company that the Company's common stock did not maintain a minimum closing bid price of $1.00 per share for the preceding 30 consecutive business days as required by NASDAQ Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The notice has no immediate effect on the listing or trading of the Company's common stock and the common stock will continue to trade on The NASDAQ Capital Market and NASDAQ First North Stockholm under the symbol "IMNP" at this time.
In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until June 2, 2018, to regain compliance with NASDAQ Listing Rule 5550(a)(2) in the United States. Compliance can be achieved automatically and without further action if the closing bid price of the Company's stock is at or above $1.00 for a minimum of 10 consecutive business days at any time during the 180-day compliance period, in which case NASDAQ will notify the Company of its compliance and the matter will be closed.
If, however, the Company does not achieve compliance with the Minimum Bid Price Requirement by June 2, 2018, the Company may be eligible for additional time to comply. In order to be eligible for such additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify NASDAQ in writing of its intention to cure the deficiency during the second compliance period.
Englewood Cliffs, New Jersey, USA - December 6, 2017
For further information, contact: firstname.lastname@example.org
This is information which Immune Pharmaceuticals Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the contact person set out above, at 8:00 CET on December 6, 2017.
Immune Pharmaceuticals Inc. is listed at Nasdaq First North Stockholm. Erik Penser Bank is the Company's Certified Adviser.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first- in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including atopic dermatitis, immune and inflammatory hepatitis, and asthma.
Safe Harbor Statements Regarding Forward Looking Statements
The statements in this news release made by representatives of Immune relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune's product candidates and the sufficiency of Immune's cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune's ability to fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that Immune will successfully complete its anticipated corporate restructuring, or that Immune will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. Immune may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune's board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward- looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune's filings with the Securities and Exchange Commission, including those discussed in Immune's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and periodic reports filed on Form 8-K.
SOURCE Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in New York, NY.
Annual Meeting to Resume Thursday, February 15, 2018
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets' Fourteenth Annual Investor Conference, to be held January 29-30 at the W Hotel in Fort Lauderdale, Florida.
Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018
Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8-10 during the most important week in healthcare investment forums at the Hilton San Francisco Union Square.
The shareholders of Immune Pharamceuticals, Inc. (First North: IMNP), (the "Company") are hereby convened to the 2017 Annual General Meeting (the "AGM") to be held on Thursday, 25 January 2018 at 4:00 PM Central European Time (CET) at the offices of Nixon Peabody LLP, 55 West 46th Street, New York, New York 10036.
Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Audit Committee of the Company notified BDO USA, LLP ("BDO") the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017, that the Company and its Audit Committee had determined to dismiss BDO effective as of December 7, 2017. On and effective as of December 7, 2017, the Company entered into an engagement letter with Marcum, LLP ("Marcum") as approved by the Audit Committee, and engaged Marcum to act as the Company's independent registered public accounting firm.
Englewood Cliffs, NJ, USA - December 13, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Company filed a preliminary proxy statement with the United States Securities and Exchange Commission ("SEC") on December 8, 2017 in connection with the Company's 2017 Annual Meeting of Stockholders, which is proposed to be held on January 25, 2018. The SEC review period for filings of this type customarily are ten (10) calendar days, but may be longer in the discretion of the SEC. The formal Notice of Annual Meeting and a definitive proxy statement more fully describing the purposes of the Annual Meeting will be distributed to all stockholders later this month following completion of the SEC approval process.
Englewood Cliffs, NJ, USA - December 11, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will have oversight of the non-clinical aspects of the Company's drug development programs, incuding all pre- clinical studies, and will provide support for the clinical, regulatory and manufacturing activities for the Company's core pipeline assets, bertilimumab and nano-cyclosporin. Dr. Zhang joins the Company from Tesaro, Inc., Boston, MA, where he served as Director, Clinical Sciences since April 2016, and Director, Toxicology and Safety Pharmacology from Sept 2012 to March 2016.
Immune Pharmaceuticals Inc
Marknadsplats: First North
Interim Report Q3 2017